Zarębska‐Michaluk D, Jaroszewicz J, Pabjan P, et al. - In chronic hepatitis C patients, researchers sought to evaluate the effectiveness and safety of an 8-week glecaprevir (GLE)/pibrentasvir (PIB) regimen depending on liver fibrosis and HCV genotype and ascertain whether an 8-week regimen is sufficient to cure HCV-infected patients in real-world settings. Chosen from the EpiTer‐2 database, a large retrospective national real‐world study assessing antiviral treatment in 12,584 people in 22 Polish hepatology centers, the sample consisted of patients who received GLE/PIB for 8 weeks. In total, 1,034 patients with female predominance (52%) were recruited in the analysis. High efficacy of 8‐week GLE/PIB treatment in a non‐GT3 population, regardless of liver fibrosis stage, has been demonstrated. Comparable efficacy has been achieved irrespective of the genotype, including GT3 HCV, in non-cirrhotic patients. Independent predictors of nonresponse in multivariate logistic regression were HCV GT‐3 and HIV infection.